drugset / Trial / NCT04126460
High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery(RePASS)
Phase 2
Unknown
41 enrolled
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
NaSingle-groupOpen-labelTreatment
Summary
This is a non-randomized, phase II, open-label study. The goal of this clinical research study is to investigate the efficacy and safety of adjuvant Toripalimab in high-risk recurrent/secondary HNSCC after salvage surgery.
Timeline
- Start
- 2019-07-10
- Primary completion
- 2021-09-30
- Completion
- 2021-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Toripalimab | Monoclonal antibody | 240 mg | — |